Hansizhuang® is the commercial brand name of Serplulimab Injection, a recombinant humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody developed by Henlius Biotech. It binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1/PD-L2, thereby restoring the immune…
CARVYKTI® is the commercial brand name of ciltacabtagene autoleucel, a BCMA-directed genetically modified autologous T-cell immunotherapy developed by Janssen Biotech. It involves engineering the patient’s own T cells to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA),…
Ensacove® is the commercial brand name of Ensartinib Hydrochloride Capsules, an orally active second-generation anaplastic lymphoma kinase (ALK) inhibitor developed by Betta Pharmaceuticals. It selectively inhibits ALK tyrosine kinase activity, blocking downstream signaling pathways to suppress the proliferation and survival…
SOLIRIS® is the commercial brand name of Eculizumab Injection, a humanized anti-C5 monoclonal antibody developed by Alexion Pharmaceuticals. It binds to complement protein C5, preventing its cleavage into C5a and C5b-9, thereby inhibiting terminal complement-mediated hemolysis and inflammation. Main IndicationsTreatment…
TEGLUTIK® is the commercial brand name of Riluzole Oral Suspension, an orally active antiglutamatergic agent. It inhibits glutamate release and blocks voltage-dependent sodium channels, exerting neuroprotective effects in amyotrophic lateral sclerosis (ALS). Main IndicationsTreatment of amyotrophic lateral sclerosis (ALS) in…
Taltz® is the commercial brand name of Ixekizumab Injection, a humanized anti-IL-17A monoclonal antibody developed by Eli Lilly. It selectively binds to interleukin 17A (IL-17A), inhibiting its interaction with the IL-17 receptor and blocking the inflammatory cascade in autoimmune diseases.…
Kisqali® is the commercial brand name of Ribociclib Tablets, an orally active CDK4/6 inhibitor developed by Novartis. It selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma (Rb) protein to arrest the cell cycle in G1…
Amaryl® is the commercial brand name of Glimepiride Tablets, an orally active sulfonylurea antidiabetic agent developed by Sanofi. It stimulates pancreatic beta cells to secrete more insulin, thereby lowering blood glucose levels. Main IndicationsTreatment of type 2 diabetes mellitus in…
Yunzhi® is the commercial brand name of Colchicine Tablets, an orally active anti-inflammatory agent developed by Yunnan Phytopharmaceutical Co., Ltd. It inhibits microtubule polymerization, thereby suppressing neutrophil migration, adhesion, and degranulation, and reducing inflammatory responses. Main IndicationsPrevention and treatment of…
Zhuoqing® is the commercial brand name of Spectinomycin Hydrochloride for Injection, an injectable aminocyclitol antibiotic developed by Shandong Lukang Pharmaceutical. It inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, exerting bactericidal activity against susceptible pathogens. Main IndicationsTreatment…